However, mainly because of primary and acquired resistance to treatments, the majority of patients will ultimately relapse, and only patients harboring a BRAF mutation, observed in about 50% of cutaneous melanoma, can receive a targeted treatment with BRAF and MEK inhibitors (Spagnolo et al., 2015). The gene discussed is BRAF; the disease is cutaneous melanoma.